Amgen kept at neutral by Merrill

Merrill Lynch analyst Eric Ende maintained Amgen, Inc. at neutral on news of the Vectibix approval by the Food and Drug Administration for colorectal cancer. The analyst expects Vectibix to gain roughly 60% of Erbitux's market based on better safety, more convenient dosing and Amgen's marketing strength. Shares of the Thousand Oaks, Calif.-based biotechnology company were down 59 cents, or 0.82%, at $71.55. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.